Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326942 | 0.78 | DHFR (0.32) | DHFR | |
| SCHEMBL23394740 | 0.78 | PGR (0.30) | — | |
| SCHEMBL19464449 | 0.78 | — | — | |
| SCHEMBL21299258 | 0.76 | — | — | |
| SCHEMBL20810798 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL27407768 | 0.73 | — | — | |
| SCHEMBL24235927 | 0.72 | — | — | |
| SCHEMBL24235930 | 0.72 | — | — | |
| SCHEMBL24043120 | 0.68 | PDPK1 (0.31) | — | |
| SCHEMBL22327066 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-04-20 | — | — | US | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| EP-4122497-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220119779-A1 | MODIFIED PYROCOCCUS POLYMERASES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-20210284975-A1 | MODIFIED PYROCOCCUS POLYMERASES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-09-16 | — | — | US | disclosed |
| US-11014950-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210138079-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210138078-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3786173-A1 | AMIDITE COMPOUND AND METHOD FOR PRODUCING POLYNUCLEOTIDE USING SAID COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2021-03-03 | — | — | EP | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | NUDT1, PNP, NT5C2 | DHFR 167/4885 |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SMN1; SMN2, UTRN, RBM17 | DHFR 1273/4885 |
| US-11014950-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | DHFR 124/4885 |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | DHFR 1385/4885 |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, DCLRE1B | DHFR 1309/4885 |
| US-20210138079-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SMN1; SMN2, UTRN, RBM17 | DHFR 1273/4885 |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | DHFR 1494/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | DHFR 208/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | DHFR 197/4885 |
| US-20210138078-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, RBM17 | DHFR 1494/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | DHFR 208/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | DHFR 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.